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Respiratory syncytial virus (RSV) is a common cause of
lower respiratory tract infections in infants and small chil-
dren worldwide. There is no cure for RSV disease, but
immunoprophylaxis using humanized monoclonal antibody
has proven to be safe and efficacious in preventing
disease. Extensive research supports the hypothesis that
RSV bronchiolitis in infancy results in increased risk for
development of wheezing, asthma, and possibly atopy
throughout childhood. In spite of this, the pathophysio-
logic mechanisms that are responsible for this association
have not been fully elucidated.
We recently co-chaired an international panel of physi-
cians that met to discuss the link between RSV and reac-
tive airway disease (RAD). Research results in the clinical
arena and current opinion on RSV prophylaxis and the
RSV–RAD association are presented in this special sup-
plement to Respiratory Research.
Professor Rosalind Smyth from the University of Liverpool,
UK, presented evidence supporting the argument that
asthma is a major pediatric health issue. The incidence of
asthma has increased considerably over the past three
decades in the UK, although since the early 1990s the
incidence of new episodes has declined. This overall
increase has been observed worldwide, but there is broad
variation between countries. Environmental factors,
genetic factors, the hygiene hypothesis, and lifestyle differ-
ences may play roles in causing asthma, but currently
there is no unifying explanation for these trends. One
hypothesis for the etiology of asthma suggests that asth-
matic children have normal lung function at birth, but
inflammatory and immunologic events in the airways, such
as those seen in RSV bronchiolitis during infancy, con-
tribute to persistence of wheeze.
Dr Nele Sigurs of Borås Central Hospital, Sweden, pre-
sented clinical perspectives on the association between
RSV and RAD. She reviewed the eight studies to date that
have compared children with and without RSV bronchioli-
tis, and all have found an increased incidence of bronchial
obstructive symptoms in the ex-bronchiolitics. There were
no significant differences in family history of atopy or
asthma in any of those studies. An increased risk for aller-
gic sensitization was observed in three of the studies. It
remains unclear whether RSV bronchiolitis alone is
responsible for these symptoms or whether other risk
factors contribute. Further studies are needed to investi-
gate the effect of RSV interventional agents in order to
resolve this issue.
Professor Peter Openshaw of the Imperial College of
Science, Technology and Medicine in London addressed
the question of whether RSV is a cause or consequence
of airway pathology. He reviewed the various inflammatory
and cytokine responses associated with RSV infection
and showed that data from animal studies support the
possibility that wheezing in childhood results from viral
bronchiolitis in infancy. The timing of severe disease
appears to be critical for the development of pulmonary
sequelae, and preventing or delaying RSV infection could
reduce the number of children who suffer from recurrent
wheeze during childhood. He concurred that prospective
interventional studies are needed.
Professor Giovanni Piedimonte of the University of Miami,
Florida, USA, proposed pathophysiologic mechanisms for
the RSV–RAD link, based on his studies in rats. He has
observed upregulation of receptors for substance P, a
proinflammatory neuropeptide, in T-lymphocyte subpopula-
tions within the bronchial-associated lymphoid tissue of
RSV-infected rats. He postulates that this mechanism
establishes important neuroimmune interactions that result
in long-term dysregulation, predisposing to airway inflamma-
tion and hyperreactivity. More importantly, these changes
were avoided if rats were administered palivizumab, a mono-
clonal antibody to the fusion protein of RSV, before or
during the early phase of infection. Therefore, results in
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animal studies suggest that prevention of RSV lower respi-
ratory tract infection with anti-RSV antibody protects
against respiratory sequelae associated with this virus.
Professor Eric Simoes of The Children’s Hospital in
Denver, Colorado, USA, reviewed the global experience
of immunoprophylaxis for RSV. He presented a com-
bined analysis of several studies that have reported hos-
pitalization rates for RSV in children who had received
palivizumab and in children who did not receive prophy-
laxis. The children were divided into three subgroups:
those with chronic lung disease (CLD) and/or bron-
chopulmonary dysplasia (BPD); premature infants born
at gestational age 29–32 weeks without CLD/BPD; and
premature infants born at gestational age 32–35 weeks
without CLD/BPD. The hospitalization rates were signifi-
cantly lower in the children who had received
palivizumab for all three groups. He also reviewed
several studies conducted in Europe and North America
that continue to support the safety and efficacy of
palivizumab.
Dr Lone Graff Stensballe of the Statens Serum Institut in
Copenhagen, Denmark, presented the design of a study
she has initiated in Denmark to investigate prospectively
the incidence of RSV infection in Denmark and factors that
predispose to or protect against serious RSV disease, and
to examine the association between severe RSV infection
and RAD. Several population-based registers will be used
to examine the influence of various biologic, social, and
environmental factors on hospitalization for RSV disease.
Professor Jan Kimpen of the University Medical Center
Utrecht, The Netherlands, concluded the session with his
examination of the impact of prevention and treatment of
RSV on development of RAD. His review of published
studies revealed that ribavirin does not appear to reduce
significantly the long-term respiratory morbidity associ-
ated with RSV bronchiolitis. Corticosteriod or bron-
chodilator therapy may improve outcomes, but only on a
short-term basis. Investigations are underway to deter-
mine whether immunoprophylaxis reduces the incidence
of RAD in children.
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